These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 3481323)

  • 21. Decrease of caffeine elimination in man during co-administration of 4-quinolones.
    Stille W; Harder S; Mieke S; Beer C; Shah PM; Frech K; Staib AH
    J Antimicrob Chemother; 1987 Nov; 20(5):729-34. PubMed ID: 3480885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical uses of nalidixic acid analogues: the fluoroquinolones.
    Høiby N
    Eur J Clin Microbiol; 1986 Apr; 5(2):138-40. PubMed ID: 3013628
    [No Abstract]   [Full Text] [Related]  

  • 23. The influence of the 4-quinolones ciprofloxacin, pefloxacin and ofloxacin on the elimination of theophylline.
    Wijnands WJ; Vree TB; Baars AM; van Herwaarden CL
    Pharm Weekbl Sci; 1987 Dec; 9 Suppl():S72-5. PubMed ID: 3481439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quinolone antimicrobial agents in acute exacerbations of chronic bronchitis.
    Maesen FP; Davies BI; Teengs JP; Baur C
    Eur J Respir Dis Suppl; 1986; 146():585-90. PubMed ID: 3465584
    [No Abstract]   [Full Text] [Related]  

  • 25. [Biotransformation of selected gyrase inhibitors].
    Borner K; Lode H
    Infection; 1986; 14 Suppl 1():S54-9. PubMed ID: 3007367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [New oral quinolone compounds in chronic bronchitis].
    Davies BI; Maesen FP; Teengs JP; Baur C
    Infection; 1986; 14 Suppl 1():S73-8. PubMed ID: 2937739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapeutic drug monitoring of fluoroquinolone].
    Matsumoto F; Takahashi T; Morita M
    Nihon Rinsho; 1990 Feb; 48 Suppl():1217-22. PubMed ID: 2355524
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacokinetics of fluorinated 4-quinolones in the aged.
    Norrby SR; Ljungberg B
    Rev Infect Dis; 1989; 11 Suppl 5():S1102-6. PubMed ID: 2672244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review on the impact of 4-quinolones on the normal oropharyngeal and intestinal human microflora.
    Edlund C; Nord CE
    Infection; 1988; 16(1):8-12. PubMed ID: 3283041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of quinolones in renal insufficiency.
    Fillastre JP; Leroy A; Moulin B; Dhib M; Borsa-Lebas F; Humbert G
    J Antimicrob Chemother; 1990 Oct; 26 Suppl B():51-60. PubMed ID: 2124213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quinolone penetration into canine vaginal and urethral secretions.
    Gasser TC; Graversen PH; Larsen EH; Dørflinger T
    Scand J Urol Nephrol Suppl; 1987; 104():101-5. PubMed ID: 3481457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The comparative activity of twelve 4-quinolone antimicrobials against Haemophilus influenzae and Streptococcus pneumoniae.
    Ridgway GL; O'Hare MD; Felmingham D; Grüneberg RN
    Drugs Exp Clin Res; 1985; 11(4):259-62. PubMed ID: 2941258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative in-vitro activity of five fluoroquinolones against mycobacteria.
    Davies S; Sparham PD; Spencer RC
    J Antimicrob Chemother; 1987 May; 19(5):605-9. PubMed ID: 3112094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The comparative in vitro activity of twelve 4-quinolone antimicrobials against enteric pathogens.
    O'Hare MD; Felmingham D; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1985; 11(4):253-7. PubMed ID: 2941257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quinolones in the treatment of bronchopulmonary infections.
    Thys JP
    Rev Infect Dis; 1988; 10 Suppl 1():S212-7. PubMed ID: 3279495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Sensitivity of obligate anaerobes to ofloxacin, pefloxacin, enoxacin and norfloxacin].
    Dubreuil L; Devos J; Romond C; Bryskier A
    Pathol Biol (Paris); 1985 May; 33(5):421-5. PubMed ID: 3162143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparative in vitro activity of 10 new 4-quinolones against enteropathogenic bacteria].
    Habiyaremye I; Verbist L; Vandepitte J
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):800-4. PubMed ID: 3116489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New synthetic quinolone antibacterial agents and serum concentration of theophylline.
    Niki Y; Soejima R; Kawane H; Sumi M; Umeki S
    Chest; 1987 Oct; 92(4):663-9. PubMed ID: 3477409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Gyrase inhibitors: unwanted central nervous system effects].
    Rietbrock N; Staib AH
    Dtsch Med Wochenschr; 1987 Jan; 112(5):201. PubMed ID: 3467948
    [No Abstract]   [Full Text] [Related]  

  • 40. Interaction between quinolones and caffeine.
    Staib AH; Stille W; Dietlein G; Shah PM; Harder S; Mieke S; Beer C
    Drugs; 1987; 34 Suppl 1():170-4. PubMed ID: 3481318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.